Matthew Baggot
Neuroscientist and CEO of Tactogen
Data updated
Research Footprint
Matthew Baggot appears in 6 tracked papers (2000–2024), most studied alongside MDMA, LSD and Mescaline, across Healthy Volunteers, PTSD and Interpersonal Functioning & Social Connectedness.
Most-cited paper: The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? (104 citations).
Frequent co-authors: Harriet de Wit, Gillinder Bedi and Matthew Kirkpatrick.
Background & Research
Matthew John Baggott is an American neuroscientist and entrepreneur focused on entactogens, psychedelics, and drug development. He earned a bachelor's degree from the University of Chicago and a PhD in neuroscience from UC Berkeley, and he has conducted human laboratory studies of MDMA and related compounds. He is co-founder and CEO of Tactogen, a company developing MDMA-like medicines.
Key Impact
He is a leading MDMA/entactogen researcher whose work has helped characterize the drug’s effects on emotion, social behavior, and therapeutic potential in humans.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Affiliations
Institutions, companies, and organisations Matthew Baggot is associated with.
Tactogen
Public Benefit CorpTactogen is a Palo Alto-based public benefit corporation developing novel MDMA-like entactogens and psychedelic-adjacent molecules for psychiatric disorders. Founded in 2020 by neuroscientist Matthew Baggott and Luke Pustejovsky, Tactogen has built the largest known library of entactogenic compounds. Lead candidate TACT908 is a non-hallucinogenic 5-HT1B/2A agonist for cluster headache, while TACT833 targets alcohol use disorder and eating disorders. Following the 2024 FDA rejection of Lykos's MDMA, Tactogen has pivoted toward its novel NCE pipeline.
View stakeholder →Noetic Fund
Noetic Fund is a Toronto-based venture firm investing in early-stage technologies focused on mental health and wellbeing. Its public materials describe a diversified strategy across novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables, and other evidence-backed solutions, with a global outlook and emphasis on early intervention and prevention. The firm is explicitly tied to the psychedelic medicine ecosystem through its own fund announcements, reading list, and portfolio disclosures. Publicly named investments include CaaMTech, the Alexander Shulgin Research Institute, and Damona Pharmaceuticals, which positions Noetic as an active capital provider in psychedelic drug development and adjacent mental health innovation.
View stakeholder →Journey Clinical
Care-delivery platform for ketamine-assisted psychotherapy enabling licensed therapists to deliver KAP through a coordinated technology and prescriber network model.
View stakeholder →